Clinical trial · no report yet · Phase 2
ARION
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
- NCT03777813 ↗
- Completed
- UNICANCER
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Esophagus Cancer; Unresectable Malignant Neoplasm
- Interventions
- Durvalumab; IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 112
- Primary outcomes
- cPFS (centrally reviewed cPFS)
- Sponsor
- UNICANCER
- Start
- Dec 5, 2018
- Primary completion
- May 24, 2024
- Results posted
- No
- Registry record
- NCT03777813 · updated Nov 18, 2025